{"nctId":"NCT00419341","briefTitle":"Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy","startDateStruct":{"date":"2006-11"},"conditions":["Primary Immune Deficiency"],"count":49,"armGroups":[{"label":"IgPro20","type":"EXPERIMENTAL","interventionNames":["Biological: Human Normal Immunoglobulin for Subcutaneous Administration"]}],"interventions":[{"name":"Human Normal Immunoglobulin for Subcutaneous Administration","otherNames":["Hizentra"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female aged 2 to 75 years\n* Subjects with primary humoral immunodeficiency, namely with a diagnosis of: CVID (Common Variable Immunodeficiency) as defined by PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies) or XLA (X-linked Agammaglobulinemia)\n* Written informed consent\n\nExclusion Criteria:\n\n* Newly diagnosed PID\n* Evidence of an active serious infection at the time of screening (i.e., but not limited to: bacteremia/septicemia, pneumonia, fungal osteomyelitis)\n* Malignancies of lymphoid cells such as lymphocytic leukemia, Non-Hodgkin's lymphoma and immunodeficiency with thymoma\n* Known hyperprolinemia\n* Hypoalbuminemia, protein-losing enteropathies, and any proteinuria\n* Allergic reactions to immunoglobulins or other blood products\n* Known antibodies to Immunoglobulin A (IgA)\n* The subject is receiving steroids (oral and parenteral, daily â‰¥ 0.15 mg of prednisone equivalent/kg/day) or other systemic immunosuppressants\n* Female who is pregnant, breast feeding or planning a pregnancy during the course of the study\n* Participation in a study with an investigational product other than (IVIG) within 1 month prior to enrollment\n* A positive result at screening on any of the following viral markers: Human Immunodeficiency Virus (HIV), Hepatitis C virus (HCV) and Hepatitis B virus (HBV)\n* Aspartate aminotransferase (ASAT) or Alanine aminotransferase (ALAT) concentration \\> 2.5 times the upper normal limit (UNL)\n* Creatinine concentration \\> 1.5 times the UNL\n* Any condition that is likely to interfere with evaluation of the study drug or satisfactory conduct of the trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"75 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs) (MITT Population)","description":"The annualized rate was based on the total number of SBIs and the total number of subject study days during the efficacy period for all subjects in the specified analysis population and adjusted to 365 days.\n\nPotential SBIs included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an adverse event (AE) was identified as a potential SBI, the AE was adjudicated by a review committee to determine if the event fulfilled the predefined criteria for SBIs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]}]},{"type":"PRIMARY","title":"Area Under the Concentration-time Curve (AUC) of Total Serum Immunoglobulin G (IgG)","description":"Evaluate non-inferiority of steady-state IgG area under the concentration-time curves standardized to a 7-day period (sAUCs) for subcutaneous immunoglobulin (SCIG) (IgPro20) versus the sAUC under intravenous immunoglobulin (IVIG) (Privigen) treatment. The sAUC under IVIG was taken from the same subjects in a preceding study (either ZLB03\\_002CR \\[NCT00168025\\] or ZLB05\\_006CR \\[NCT00322556\\]).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105.6","spread":"31.56"},{"groupId":"OG001","value":"103.2","spread":"20.00"}]}]}]},{"type":"SECONDARY","title":"Annualized Rate of Clinically Documented SBIs (ITT Population)","description":"The annualized rate was based on the total number of SBIs and the total number of subject study days during the study for all subjects in the specified analysis population and adjusted to 365 days.\n\nPotential SBIs included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an AE was identified as a potential SBI, the AE was adjudicated by a review committee to determine if the event fulfilled the predefined criteria for SBIs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Rate of Clinically Documented SBIs (PPE Population)","description":"The annualized rate was based on the total number of SBIs and the total number of subject study days during the efficacy period for all subjects in the specified analysis population and adjusted to 365 days.\n\nPotential SBIs included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess. If an AE was identified as a potential SBI, the AE was adjudicated by a review committee to determine if the event fulfilled the predefined criteria for SBIs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Rate of Infection Episodes","description":"The annualized rate was based on the total number of infection episodes occurring during the efficacy period (N = 96) divided by the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.76","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Infection Episodes (Serious and Non-serious)","description":"Total number of infections for the specified analysis population","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Daily Activities Due to Infections","description":"The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection (N = 71), and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days Out of Work / School / Kindergarten / Day Care or Unable to Perform Normal Daily Activities Due to Infections","description":"Total number of days out of work / school / kindergarten / day care or unable to perform normal daily activities due to infections, for the specified analysis population","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Rate of Hospitalization Due to Infection","description":"The annualized rate was based on the total number of days of hospitalization due to infection (N = 7) and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days of Hospitalization Due to Infections","description":"Total number of days of hospitalization due to infections for the specified analysis population","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Use of Antibiotics for Infection Prophylaxis and Treatment","description":"Annualized rate of days with antibiotics for infection prophylaxis and treatment. The annualized rate was based on the total number of days of antibiotic use for infection prophylaxis and treatment in the efficacy period, and the total number of subject study days for all subjects in the specified analysis population, and adjusted to 365 days.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.52","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Serum IgG Trough Levels","description":"The IgG trough values per subject were aggregated to a median value, and then median values across subjects were summarized using descriptive statistics.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.53","spread":"3.21"}]}]}]},{"type":"SECONDARY","title":"Maximum Concentration (Cmax) of Total Serum IgG at Steady State","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.16","spread":"4.93"}]}]}]},{"type":"SECONDARY","title":"Tmax at Steady State","description":"Timepoint of maximum concentration (Cmax)","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.118","spread":"1.7729"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Minimum Concentration (Cmin) of Total Serum IgG at Steady State","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.70","spread":"4.39"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Rate of All AEs by Relatedness and Seriousness","description":"The rate of AEs was the number of AEs over the number of infusions administered. At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.773","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.634","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.004","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Rate of Mild, Moderate, or Severe Local Reactions","description":"In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of injection site reaction, injection site bruising, infusion site scab, injection site cyst, injection site eczema, injection site irritation, injection site nodule, and injection site pain.\n\nMild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.592","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.553","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.038","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.002","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":49},"commonTop":["Injection site reaction","Sinusitis","Headache","Nasopharyngitis","Cough"]}}}